N/A N=60 Clinical Studies on Bile Acids in Barrett's Esophagus
Gastroesophageal Reflux Disease
Primary: Protection Against DNA Damage by UDCA — 1.068; .82 Relative Densitometry Units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=7 Optical Frequency Domain Imaging (OFDI) for Biliary Stricture Imaging
Biliary Stricture
Primary: Feasibility of Imaging the Bile Duct With the OFDI Probe — 7 Participants
N/A N=197 Pancreaticobiliary Reflux in Patients Without Cholelithiasis
Pancreaticobiliary Reflux
Primary: Amylase and Lipase Values in Gallbladder Bile — 5.5; 181.2; 9.5; 434.8 mg/dl
N/A N=129 A Trial Comparing the Uncovered to the Covered Wallstent in the Palliation of Malignant Bile Duct Strictures
Inoperable Tumors of the Bile Duct
Primary: Time to Recurrent Biliary Obstruction — 711; 357 days — p=0.530
Phase 1 N=22 Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT
Cholestasis · Primary Sclerosing Cholangitis · Primary Biliary Cirrhosis
Primary: Percentage of Participants in Whom we Could Quantify Hepatic Transport of 11C-CSar — 100; 100 percentage of participants
Phase 4 N=23 Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy
Bile Acid Malabsorption · Cholelithiasis
Primary: Change in Stimulated Fibroblast Growth Factor 19 (FGF19) From Baseline Before Versus Post Cholecystectomy — 81; 186 pg per mL — p=0.03
N/A N=7 Evaluation of Pancreatobiliary Disorders in Patients With Altered Gastric Anatomy
Pancreatobiliary Disease · Altered Gastric Anatomy
Primary: Papilla or Duct-enterostomy Was Reached — 10 ERCPs
N/A N=211 Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers
Periampullary Cancers With Obstructive Jaundice · Pancreas Head Cancer · Bile Duct Cancer
Primary: Incidence of Infectious Complications After Biliary Drainage — 11; 5 participants
Phase 2 N=13 N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy
Biliary Atresia
Primary: Number of Patients With Biliary Atresia (BA) Achieving Total Serum Bile Acids Less Than or Equal to 10 *U*Mol/L Within 24 Weeks of Kasai Portoenterostomy (KP) — 0…
Phase 3 N=187 WallFlex Biliary Fully Covered (FC) Benign Stricture Study
Biliary Stricture
Primary: Stent Removability — 132 Participants
N/A N=16 Characterization of Bile Acid Pathway in Obesity
Obesity
Primary: Change in 48h-fecal Bile Acid Excretion (μmol/L) Between Baseline and High Fat Diet — 543; 344 (μmol/L)/48 hour
N/A N=75 The Clinical Utility of Cholangioscopy and Pancreatoscopy in the Diagnosis and Management of Pancreaticobiliary Disorders
Disorders of the Pancreas and Biliary Tree
Primary: Successful Procedure Completion — 70; 5 participants
N/A N=677 Fluorescent Cholangiography vs White Light for Bile Ducts Identification
Cholecystitis · Cholelithiasis
Primary: Detection Rate of Common Bile Duct Before and After Dissection Using Near Infra-red Light — 64; 157; 159; 243 Participants
Phase 3 N=5 GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis
Bile Acid Synthesis Defect · Inborn Error of Bile Acid Metabolism · Inborn Error of Bile Acid Conjugation
Primary: Conjugated Cholic Acid (GCA) for the Treatment of Inborn Errors in Bile Acid Synthesis Involving Side-chain Conjugation. — 5 Participants
Phase 2 N=111 Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.
Primary Biliary Cirrhosis
Primary: The Percent Change in Serum GGT. — -4.9; -19; -8.4 percent change
Phase 2 N=23 Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus
Type 2 Diabetes Mellitus · Obese · Overweight
Primary: Change in Postprandial Glucose — -2803; 629 mmol/6hr — p=<0.05
Phase 2 N=28 Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Advanced Bile Duct Carcinoma · Advanced Gallbladder Carcinoma · Refractory Bile Duct Carcinoma
Primary: Progression-free Survival (PFS) — 37.0 percentage of participants
Phase 2 N=20 Pentoxifylline for Primary Biliary Cirrhosis
Primary Biliary Cirrhosis
Primary: Change in Serum Alkaline Phosphatase Levels. — -57.3 U/L — p=0.001
N/A N=70 Study of the WallFlex™ Biliary Partially-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction
Biliary Strictures Caused by Malignant Neoplasms
Primary: Number of Participants With Absence of Recurrent Biliary Obstruction — 62 Participants
N/A N=115 Study to Compare the Incidence of Biliary Complications After Liver Transplantation
Liver Transplant; Complications
Primary: Number of Participants With Biliary Complications — 19; 12 participants
Phase 2 N=24 Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
Primary Biliary Cholangitis · Primary Biliary Cirrhosis · Cholangitis
Primary: Percent Change in Alkaline Phosphatase (ALP) at Week 12 Compared to Baseline — -7.7 percent change — p==0.077
N/A N=119 Early Identification of Myocardial Impairment in PBC
Primary Biliary Cholangitis · Cardiovascular Abnormalities
Primary: The Incidence of Cardiac Events — 0; 0; 0; 0 Participants — p=0.001
N/A N=112 Covered Metallic Stents for First-Line Treatment of Benign Bile Duct Strictures
Common Bile Duct Stricture
Primary: Early Clinical Success — 50; 41 Participants
Phase 3 N=74 A Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction
Cholestasis, Extrahepatic
Primary: Adequate Clinical Palliation of the Biliary Obstruction — 54 participants
N/A N=23 Evaluation of the Use of Metal Stents as Part of the Treatment of Benign Biliary Strictures
Benign Biliary Strictures
Primary: Short Term Success Rate in the Resolution of Biliary Strictures — 22; 14; 3; 5 participants
Phase 2 N=35 Obeticholic Acid in Bile Acid Diarrhoea
Primary Bile Acid Malabsorption · Secondary Bile Acid Malabsorption · Chronic Diarrhoea
Primary: Changes in Fasting FGF19 — 71; 25; 130 percentage increase of baseline — p=0.007
Phase 2 N=28 TAS-102 in Treating Advanced Biliary Tract Cancers
Cholangiocarcinoma · Stage III Gallbladder Cancer AJCC v7 · Stage IIIA Gallbladder Cancer AJCC v7
Primary: 16-Week Progression-free Survival (PFS) Rate — 32.0 percentage of patients
N/A N=10 WallFlex Biliary Post Liver Transplant IDE Pilot
Anastomotic Biliary Stricture Post Orthotopic Liver Transplant
Primary: Stricture Resolution at the Time of Stent Removal. — 9; 1 participants
N/A N=140 A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy
Biliary Atresia
Primary: The Percentage of Patients With Serum Total Bilirubin <1.5 mg/dL and With Native Liver at 6 Months After Portoenterostomy — 58.6; 48.6 percentage of participants — p=0.43
Phase 4 N=16 Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis
Primary Biliary Cirrhosis
Primary: Biochemical Response — 1 Participants